Novel mHealth Platform to Ensure Quality of Community-based Malaria Diagnosis

Quality Assurance of Malaria Diagnosis Clinical Trial

Official title:

Novel mHealth Platform to Ensure Quality of Community-based Malaria Diagnosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02504593
• Other study ID #: Pro00063521
• Status: Completed
• Phase: N/A
• First received: July 2, 2015
• Last updated: May 24, 2016
• Start date: July 2015
• Est. completion date: April 2016

Study information

• Verified date: April 2016
• Source: Duke University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review BoardKenya: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The investigators propose to implement a new mobile interface that automatically reads and troubleshoots malaria rapid diagnostic test (RDT) cassettes. This device, called a Deki reader (DR), will allow the investigators to establish an extensive quality assurance program of malaria diagnosis performed by trained community health volunteers (CHVs). The study will lease 10 DRs and rotate them amongst 200 CHVs performing community-based malaria diagnosis through rapid diagnostic testing. The study setting is Bungoma East subcounty and Kiminini subcounty in Kenya. The overall goal is to measure and improve the quality of malaria diagnosis by CHVs using malaria RDTs. The investigators aim for every CHW to exceed 90% sensitivity and specificity and zero operator errors within six months. There are no appreciable risks to the CHV associated with evaluation by the DR device. The investigators' analysis will focus on descriptive statistics of RDT use and accuracy amongst all participating CHVs.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: April 2016
• Est. primary completion date: April 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• All community health volunteers in 10 community units in Bungoma East and 6 community units in Kiminini that have been trained to provide community-based malaria diagnosis through rapid diagnostic testing are eligible.

Exclusion Criteria:

• Any person not meeting the inclusion criteria.

Study Design

Intervention Model: Single Group Assignment

Related Conditions & MeSH terms

• Malaria
• Quality Assurance of Malaria Diagnosis

Intervention

Device:
• mHealth platform employing Fionet Deki Readers to ensure quality of community-based malaria diagnosis
The investigators propose to implement a new mobile interface that automatically reads and troubleshoots malaria rapid diagnostic test (RDT) cassettes. This device, called a Deki reader (DR), will allow the investigators to establish an extensive quality assurance program of malaria diagnosis performed by trained community health volunteers (CHVs). To ensure high-quality diagnosis by CHVs, the study team will deploy 10 Fionet DRs and rotate them amongst 200 CHVs who have been trained to do RDTs. In the first phase, each CHV will use the device for 10 successive clients presenting themselves for malaria diagnosis to the CHV, and then the device will be rotated to another CHV.

Locations

Country	Name	City	State
Kenya	Duke University	Eldoret

Sponsors (1)

Lead Sponsor	Collaborator
Duke University

Country where clinical trial is conducted

Kenya, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percent of RDTs with correct administration and interpretation by CHVs compared across the first and tenth tests	The percent of RDTs that were properly conducted and interpreted by CHVs, according to Deki Reader results, comparing across the first and tenth RDTs read with the Deki Reader for each CHV.	6 months (during which each consenting CHV of the 200 eligible will conduct 10 tests)	No
Secondary	Percent of RDTs with a false negative reading by CHVs compared across the first and tenth tests	Percent of RDTs with a false negative reading by CHVs compared across the first and tenth tests read with the Deki Reader for each CHV.	6 months	No
Secondary	Percent of RDTs with a false positive reading by CHVs compared across the first and tenth tests	Percent of RDTs with a false positive reading by CHVs compared across the first and tenth tests read with the Deki Reader for each CHV.	6 months	No
Secondary	Percent of invalid RDTs not properly identified by CHVs compared across the first and tenth tests	Percent of invalid RDTs not properly identified by CHVs compared across the first and tenth tests read with the Deki Reader for each CHV.	6 months	No
Secondary	Percent of RDTs that CHVs performed with an improper test procedure compared across the first and tenth tests.	Percent of RDTs that CHVs performed with an improper test procedure compared across the first and tenth tests read with the Deki Reader for each CHV.	6 months	No
Secondary	Overall sensitivity (measured as the proportion of positive tests as determined by the DR which the CHVs correctly identify).	Overall sensitivity of RDTs performed by CHVs compared to the Deki Reader results. Sensitivity will be measured as the proportion of positive tests as determined by the DR which the CHVs correctly identify.	6 months	No
Secondary	Overall specificity (measured as the proportion of negative tests as determined by the DR which the CHVs correctly identify).	Overall specificity of RDTs performed by CHVs compared to the Deki Reader results. Specificity will be measured as the proportion of negative tests as determined by the DR which the CHVs correctly identify.	6 months	No